Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$296.47 +2.1%	$293.30	$253.30 ▼ $339.17	$159.61B	0.49	2.13 million shs	2.17 million shs
BIIB Biogen	$138.60 +2.7%	$130.13	$110.04 ▼ $207.59	$20.32B	0.13	1.53 million shs	1.64 million shs
INCY Incyte	$86.92 +0.9%	$71.91	$53.56 ▼ $87.06	$16.97B	0.71	1.90 million shs	1.88 million shs
LLY Eli Lilly and Company	$701.51 +2.5%	$764.55	$623.78 ▼ $972.53	$663.68B	0.44	6.35 million shs	8.21 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	+2.86%	-0.60%	+8.83%	-8.14%
BIIB Biogen	0.00%	+6.07%	+7.70%	+10.36%	-30.90%
INCY Incyte	0.00%	+10.88%	+26.08%	+37.29%	+42.07%
LLY Eli Lilly and Company	0.00%	+12.21%	-7.94%	-7.36%	-24.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.6662 of 5 stars	2.2	4.0	3.3	3.9	2.8	2.5	1.9
BIIB Biogen	4.8637 of 5 stars	4.2	3.0	0.0	3.7	3.9	2.5	1.9
INCY Incyte	4.6564 of 5 stars	2.2	2.0	0.0	2.8	3.3	3.3	4.4
LLY Eli Lilly and Company	4.9986 of 5 stars	4.4	5.0	3.3	4.0	3.3	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.33	Hold	$303.76	2.46% Upside
BIIB Biogen	2.34	Hold	$185.74	34.01% Upside
INCY Incyte	2.33	Hold	$81.20	-6.58% Downside
LLY Eli Lilly and Company	2.71	Moderate Buy	$964.88	37.54% Upside

Current Analyst Ratings Breakdown

Latest LLY, AMGN, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00 ➝ $118.00
8/14/2025	LLY Eli Lilly and Company	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$975.00 ➝ $825.00
8/13/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$942.00 ➝ $875.00
8/11/2025	LLY Eli Lilly and Company	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,010.00 ➝ $900.00
8/8/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,050.00 ➝ $895.00
8/7/2025	LLY Eli Lilly and Company	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2025	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$715.00
8/6/2025	AMGN Amgen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$305.00 ➝ $310.00
8/6/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$330.00 ➝ $333.00
8/6/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$326.00 ➝ $317.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.78	$30.38 per share	9.76	$13.80 per share	21.48
BIIB Biogen	$9.68B	2.10	$23.10 per share	6.00	$120.28 per share	1.15
INCY Incyte	$4.58B	3.70	$0.55 per share	157.01	$21.36 per share	4.07
LLY Eli Lilly and Company	$45.04B	14.74	$14.24 per share	49.26	$19.39 per share	36.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$12.23	24.24	13.86	2.55	18.96%	174.71%	13.12%	10/29/2025 (Estimated)
BIIB Biogen	$1.63B	$10.46	13.25	8.39	1.09	15.31%	13.85%	8.32%	10/29/2025 (Estimated)
INCY Incyte	$32.62M	$4.40	19.75	13.29	0.69	18.99%	21.99%	14.43%	11/4/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$15.30	45.85	22.54	0.98	25.91%	92.72%	16.89%	10/29/2025 (Estimated)

Latest LLY, AMGN, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
7/31/2025	Q2 2025	BIIB Biogen	$3.93	$5.47	+$1.54	$4.33	$2.32 billion	$2.65 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.21%	N/A	77.84%	14 Years
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.86%	N/A	39.22%	11 Years

Latest LLY, AMGN, BIIB, and INCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025
6/23/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.78%	8/15/2025	8/15/2025	9/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	7.24	1.31	0.98
BIIB Biogen	0.36	2.50	1.79
INCY Incyte	0.01	2.85	2.78
LLY Eli Lilly and Company	1.86	1.28	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
BIIB Biogen	87.93%
INCY Incyte	96.97%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
BIIB Biogen	0.18%
INCY Incyte	17.80%
LLY Eli Lilly and Company	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	28,000	538.36 million	534.27 million	Optionable
BIIB Biogen	7,605	146.62 million	146.35 million	Optionable
INCY Incyte	2,617	195.28 million	160.52 million	Optionable
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable

LLY, AMGN, BIIB, and INCY Headlines

Recent News About These Companies

Eli Lilly and Company (LLY) Releases Q2 2025 Results

12 minutes ago | insidermonkey.com

Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Lisa C. McClain

August 16 at 8:09 PM | marketbeat.com

Eli Lilly and Company Launch “The Court is Her’s” Initiative Enticing Girls to Play Basketball

August 16 at 6:17 PM | pharmexec.comP

Pharmaceutical Stocks To Add to Your Watchlist - August 15th

August 16 at 2:55 PM | marketbeat.com

Jim Cramer names his top 5 stock picks, dismisses dot-com style meltdown

August 16 at 2:51 PM | finbold.comF

Eli Lilly and Company (NYSE:LLY) Stock Price Up 1% - Here's Why

August 16 at 1:40 PM | marketbeat.com

Eli Lilly (LLY) Insider Buys Over $1 Million in Shares

August 16 at 11:57 AM | gurufocus.com

Eli Lilly’s Stock Soars Amid Promising Trials

August 16 at 10:09 AM | tipranks.com

Cantor Fitzgerald Issues Positive Forecast for LLY Earnings

August 16 at 10:03 AM | marketbeat.com

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.

August 16 at 10:01 AM | fool.com

Texas Lawsuit Filed Against Eli Lilly (LLY) Amid New Cardio Collaboration

August 16 at 8:15 AM | finance.yahoo.com

State of New Jersey Common Pension Fund D Has $224.45 Million Holdings in Eli Lilly and Company (NYSE:LLY)

August 16 at 7:31 AM | marketbeat.com

Eli Lilly and Company (NYSE:LLY) Position Trimmed by Oak Grove Capital LLC

August 16 at 7:21 AM | marketbeat.com

American Century Companies Inc. Sells 330,070 Shares of Eli Lilly and Company (NYSE:LLY)

August 16 at 7:20 AM | marketbeat.com

EverSource Wealth Advisors LLC Grows Holdings in Eli Lilly and Company (NYSE:LLY)

August 16 at 7:05 AM | marketbeat.com

Martin Currie Ltd. Sells 2,580 Shares of Eli Lilly and Company (NYSE:LLY)

August 16 at 6:55 AM | marketbeat.com

Eli Lilly and Company (NYSE:LLY) Stock Acquired Rep. Lisa C. McClain

August 16 at 5:03 AM | marketbeat.com

Investors Buy Large Volume of Eli Lilly and Company Call Options (NYSE:LLY)

August 16 at 3:25 AM | americanbankingnews.com

Guggenheim Has Lowered Expectations for Eli Lilly and Company (NYSE:LLY) Stock Price

August 16 at 3:25 AM | americanbankingnews.com

Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes

August 16 at 3:14 AM | msn.com

Eli Lilly hikes Mounjaro prices in the UK to make weight-loss drug cheaper in the US

August 16 at 3:14 AM | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, AMGN, BIIB, and INCY Company Descriptions

Amgen NASDAQ:AMGN

$296.47 +6.18 (+2.13%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$296.32 -0.15 (-0.05%)

As of 08/15/2025 07:58 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Biogen NASDAQ:BIIB

$138.60 +3.66 (+2.71%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$139.51 +0.91 (+0.66%)

As of 08/15/2025 07:58 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$86.92 +0.76 (+0.88%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$86.92 0.00 (-0.01%)

As of 08/15/2025 07:49 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Eli Lilly and Company NYSE:LLY

$701.51 +17.08 (+2.50%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$702.75 +1.24 (+0.18%)

As of 08/15/2025 08:00 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time